1. At a Glance – The Quarter That Shut the Trolls Up
Glenmark Pharmaceuticals just dropped a Q3 FY26 result that feels like a Bollywood redemption montage. Consolidated revenue came in at ₹39,006 mn, EBITDA at ₹8,697 mn, and PAT at ₹4,032 mn. Yes, that PAT number is chunky, and yes, it includes settlements and one-offs—but cash is cash, boss. The stock sits around ₹2,016, market cap near ₹56,889 cr, P/E ~21x, ROCE 19.4%, ROE 15.8%, and debt a very polite ₹1,224 cr.
Three-month return is positive, one-year return is spicy, and sentiment has flipped from “FDA nightmare fuel” to “okay maybe management knows what it’s doing.” India formulations are back in rhythm, the US injectable story is restarting from Monroe, Europe is behaving, and RYALTRIS is traveling the world like a diplomatic passport.
Question for you already: Is this a one-quarter sugar rush or the start of a multi-year clean-up story?
2. Introduction – Once Upon a Time in Glenmark-land
For years, Glenmark lived a double life. On one side, a serious research-led pharma company with dermatology, respiratory, and oncology muscle. On the other, a walking FDA anxiety attack with US pricing pressure, facility warnings, and investors refreshing the announcements page like day traders on expiry day.
Q3 FY26 doesn’t magically erase the past, but it does something important—it changes the tone. Settlements are largely behind, Monroe is back, Aurangabad cleared USFDA inspection with zero 483s, and the balance sheet looks like it’s been to therapy.
Add to this the AbbVie deal cash, specialty pipeline progress via Ichnos, and branded respiratory traction globally, and suddenly Glenmark doesn’t look like “that risky midcap pharma” anymore. It looks… organised. Slightly dangerous still, but organised.
Be honest—when was the last time Glenmark results didn’t give you heartburn?
3. Business Model – WTF Do They Even Do?
Think of Glenmark as a three-headed hydra:
- India Formulations – Strong chronic play: respiratory, dermatology, cardiac, diabetes. Ranked 2nd in respiratory, 2nd in derma, 5th in cardiac. This is where brands, doctors, and MR armies matter.
- Global Generics (US, Europe, RoW) – Oral solids, injectables, respiratory devices, complex generics. Painful but scalable.
- Innovation / Specialty (Ichnos) – Oncology and autoimmune assets. High burn, high optionality, high drama.
They sell tablets, creams, inhalers, injectables, biosimilars, and dreams of blockbuster molecules. Manufacturing spans 14 facilities across 4 continents, 8 USFDA-approved, which is both a strength and a compliance headache.
Simple version: Cash today from generics + optional jackpot tomorrow from innovation.
Lazy-investor test: If you hate R&D risk, do you even belong in Glenmark?
4. Financials Overview – Numbers That Actually Matter
Quarterly Comparison (₹ mn)
| Metric | Latest Qtr (Q3 FY26) | YoY Qtr | Prev Qtr | YoY % | QoQ % |
|---|---|---|---|---|---|
| Revenue | 39,006 | 33,880 | 60,469 | 15.2% | -35.5% |
| EBITDA | 8,697 | 6,002 | 23,596 | 44.9% | -63.1% |
| PAT | 4,032 | 2,598 | 610 | 55.2% | 561% |
| EPS (₹) | 14.29 | 12.33 | 21.63 | 15.9% | -33.9% |
Annualised EPS (Q3 rule)
Average of Q1–Q3 FY26 EPS ≈ ₹37–38, broadly aligning with TTM ₹37.7.
Witty takeaway: Operationally improving, cosmetically boosted, structurally healing.
So tell me—do you adjust for one-offs, or do you just enjoy the PAT glow-up?
5. Valuation Discussion – Fair Value Range Only (No Hype Allowed)
Method 1: P/E
- Normalised EPS range: ₹35–40
- Reasonable multiple: 18x–24x
- Implied value band: ₹630 – ₹960 (per EPS unit, scaled to CMP context)
Method 2: EV/EBITDA
- TTM EBITDA ~₹43,710 mn
- EV/EBITDA range: 10x–14x
- Equity value broadly supports current zone with upside if margins sustain.
Method 3: DCF (Conservative)
- Low single-digit volume growth
- Stable margins
- Heavy R&D drag maintained
Fair Value Range: Broad, not precise.
This fair value range is for educational purposes only and is not investment advice.
6. What’s Cooking – News, Triggers, Drama
- US$700m AbbVie upfront received via IGI—balance sheet went from stressed to chilled.
- US Zetia/Vytorin antitrust settlements largely closed—legal overhang reduced.
- Aurangabad USFDA inspection: zero 483s—rare pharma flex.
- Monroe facility restarted—injectables back on the menu.
- RYALTRIS approvals across China, EU, RoW—respiratory franchise scaling.
- Biosimilar Lirafit launched in India at ~70% lower therapy cost.
Serious question: How many pharma companies do you know that cleaned legal mess + restarted plants + monetised R&D in one year?
7. Balance Sheet – Still Standing, Looking Healthier
Latest consolidated quarter used: Sep FY26
| ₹ Cr | Sep FY26 |
|---|---|
| Total Assets | 19,002 |
| Net Worth | ~9,582 |
| Borrowings | 1,224 |
| Other Liabilities | 8,196 |
| Total Liabilities | 19,002 |
Snarky bullets:
- Debt now looks like a rounding error, not a threat.
- Other liabilities still chunky—watch settlements & provisions.
- Net worth recovery = confidence recovery.
8. Cash Flow – Sab Number Game Hai
| ₹ Cr | FY23 | FY24 | FY25 |
|---|---|---|---|
| Operating CF | 625 | -265 | -828 |
| Investing CF | -515 | 4,387 | 58 |
| Financing CF | -77 | -3,906 | 787 |
Translation: R&D + settlements eat cash, deals bring it back. Sustainable? Depends on pipeline monetisation.
9. Ratios – Sexy or Stressy?
| Ratio | Latest |
|---|---|
| ROE | 15.8% |
| ROCE | 19.4% |
| P/E | ~21x |
| PAT Margin | ~10% |
| Debt/Equity | 0.13 |
Verdict: More sexy than stressy—for now.
10. P&L Breakdown – Show Me the Money
Revenue climbed, margins expanded, PAT exploded (with help). Long-term CAGR still modest, but TTM trend finally points up.
Question: Would you forgive 5 slow years for one strong inflection?
11. Peer Comparison – Big Boys Table
Compared with Sun, Cipla, Dr Reddy’s, Lupin—Glenmark sits mid-pack on valuation, lower on consistency, higher on optionality. It’s not the safest kid, but it might be the most interesting one.
12. Miscellaneous – Promoters & Shareholding Gossip
- Promoters: ~46.6%, zero pledge—green flag.
- DIIs increasing steadily.
- FIIs trimming—classic late-entry syndrome.
Promoter roast (light): Family owns enough to care, not enough to micromanage. Ideal.
13. Corporate Governance – Angels or Devils?
Audits clean recently, disclosures heavy but transparent, restructuring logical. Past sins acknowledged, not hidden. That alone deserves some brownie points in Indian pharma.
14. Industry Roast & Macro Context – Pharma Never Sleeps
Indian pharma is stuck between US price erosion and innovation temptation. API volatility, China risk, biosimilar wars, and FDA roulette continue. Winners will be those who either scale brutally or innovate successfully. Glenmark is trying to do both—which is brave, risky, and expensive.
15. EduInvesting Verdict – The Balanced Truth
Strengths
- Strong India formulations franchise
- Respiratory brands with global traction
- Cleaned-up balance sheet
- Optionality from Ichnos pipeline
Weaknesses
- Cash flow volatility
- R&D burn
- History of regulatory scares
Opportunities
- Specialty monetisation
- Injectables revival
- Biosimilars in India
Threats
- US pricing pressure
- Clinical failure risk
- Compliance relapse
Final thought: Glenmark is no longer a broken story—but it’s not a boring one either. It’s a high-beta pharma turnaround with brains and baggage.
So tell me,are you betting on boring consistency, or controlled chaos with upside?
Written by EduInvesting Team | Date